<DOC>
	<DOCNO>NCT02361593</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety transparent cap-assisted endoscopic sclerotherapyI ( lauromacrogol injection ) management esophageal varix .</brief_summary>
	<brief_title>Transparent Cap-assisted Endoscopic Sclerotherapy</brief_title>
	<detailed_description>Endoscopic procedure play great role management esophagogastric varix . Endoscopic variceal ligation ( EVL ) recommend first line therapy primary secondary prophylaxis patient esophageal varix . Previous study show superiority EVL endoscopic injection sclerotherapy ( EIS ) , mainly low occurrence rate complication . Procedure related complication relate total amount lauromacrogol , number treatment expertise endoscopists . Transparent cap already report assist endoscopic procedure , biopsy Barret esophagus endoscopic submucosal dissection . Accuracy vision improve help transparent cap front endoscopy . We try transparent cap-assisted sclerotherapy patient hospital . Now randomize control trial conduct evaluate efficacy safety transparent cap-assisted endoscopic sclerotherapy management esophageal varix .</detailed_description>
	<mesh_term>Esophageal Gastric Varices</mesh_term>
	<criteria>Patients present hospital esophageal varix diagnose gastroscopy , without gastric varix . The age patient range 18 80 year old . Patients contraindication lauromacrogol therapy transparent cap . Patients previous upper gastrointestinal bleeding history . Patients fecal disease could greatly impact survival , uremia , advance cancer respiratory failure , et al .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>endoscopic sclerotherapy , esophageal varix , transparent cap</keyword>
</DOC>